CNBX (CNBX Pharmaceuticals) ROCE % : 0.00% (As of Nov. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CNBX Pharmaceuticals's annualized ROCE % for the quarter that ended in Nov. 2024 was 0.00%.

CNBX Pharmaceuticals ROCE % Historical Data

The historical data trend for CNBX Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals ROCE % Chart

CNBX Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

ROCE %

Get a 7-Day Free Trial

-90.37

-178.82

-5,047.13

CNBX Pharmaceuticals Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

CNBX Pharmaceuticals ROCE % Calculation

CNBX Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Aug. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Aug. 2024 )		(A: Aug. 2023 )		(A: Aug. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Aug. 2024 )		(A: Aug. 2023 )		(A: Aug. 2024 )
	=	-0.676	/	( ( (0.499 - 2.516)	+	(0.031 - 2.511) )	/ 2 )
	=	-0.676	/	( (-2.017	+	-2.48)	/ 2 )
	=	-0.676	/	-2.2485
	=	30.06 %

CNBX Pharmaceuticals's ROCE % of for the quarter that ended in Nov. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Nov. 2024 )		(Q: Aug. 2024 )		(Q: Nov. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Nov. 2024 )		(Q: Aug. 2024 )		(Q: Nov. 2024 )
	=	-0.148	/	( ( (0.031 - 2.511)	+	(0.022 - 2.537) )	/ 2 )
	=	-0.148	/	( ( -2.48	+	-2.515 )	/ 2 )
	=	-0.148	/	-2.4975
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Nov. 2024) EBIT data.

CNBX Pharmaceuticals (OTCPK:CNBX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CNBX Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CNBX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814

Website

https://www.cnbxpharma.com

CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.

Executives

Cannabics Inc.	10 percent owner	108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills	director, officer: President, CEO, CFO
North American Mining Corp	10 percent owner	6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford	director, officer: Vice-President, Secretary